Objective Objective To systematically evaluate the efficacy of Chaiqin Qingning capsules in the treatment of acute upper respiratory tract infection.Methods CNKI,Wanfang database,VIP,PubMed,Embase,Cochrane Library were searched to screen randomized controlled trials(RCTs)of Chaiqin Qingning capsule in the treatment of upper respiratory tract infection.The retrieval time limit was from the establishment of each database to May 31,2023.Review Manager 5.3 was used for Meta-analysis of eligible literatures.Results A total of 7 RCTs involving 1126 subjects were included.Meta-analysis showed that the clinical effective rate of the experimental group was higher than that of the control group,and the difference was statistically significant(RR=1.10,95％CI:1.00～1.20,P=0.05);the body temperature of the experimental group was lower than that of the control group at 6,12 and 48 h,and the difference was statistically significant(MD=-0.24,95％CI:-0.33 to-0.16,P＜0.000 01;MD=-0.50,95％CI:-0.69 to-0.32,P＜0.000 01;MD=-0.46,95％CI:-0.55 to-0.38,P＜0.000 01);there was no significant difference in the onset time of feverand the complete antipyretic time between the two groups(MD=-4.07,95％CI:-11.13 to 2.98,P=0.26;MD=-3.37,95％CI:-7.83～1.10,P=0.14);there was no significant difference in the incidence of adverse events between the two groups(RR=1.21,95％CI:0.53 to 2.76,P=0.65).Conclusion Chaiqin Qingning capsule has good antipyretic effects without obvious adverse events,which can be used for the treatment of upper respiratory tract infection patients with fever.
维普
万方数据